Pembrolizumab, marketed as Keytruda, received a supplemental FDA approval for efficacy on June 3, 2025. This regulatory action by the U.S. Food and Drug Administration signifies an expansion of the drug's approved therapeutic applications based on demonstrated effectiveness.
Background
Pembrolizumab is a drug developed by Merck Sharp Dohme. This supplemental approval pertains to its efficacy, indicating an expansion of its approved uses or patient population.
What this means
The supplemental approval for Pembrolizumab for efficacy means that the FDA has reviewed additional data demonstrating the drug's effectiveness for a new indication or patient population. This development provides clinicians with an expanded treatment option and marks a significant regulatory milestone for the drug.
Source
This information is based on a supplemental application (BLA 125514 S-173) approved by the U.S. Food and Drug Administration (FDA) on June 3, 2025. The details are available on accessdata.fda.gov.